Biodesix reports 42% revenue growth in Q1 2026 and raises full-year guidance to $108-114M

Biodesix announced strong Q1 2026 results with $25.6 million revenue, up 42% year-over-year, driven by a 29% increase in diagnostic test volumes and doubled Development Services revenue. The company improved gross margin to 84% and reduced net loss by 30%, signaling progress toward profitability. Biodesix raised its full-year 2026 revenue guidance to $108-114 million, expecting continued growth and operational leverage. This performance highlights Biodesix's expanding market presence and operational efficiency in diagnostic solutions.